Short bowel syndrome (SBS) is a rare condition that occurs when a significant portion of the small intestine is surgically removed, resulting in malabsorption and malnutrition. The global SBS market is expected to experience growth due to an increase in the incidence of SBS and the availability of various treatment options. The market is driven by factors such as advancements in medical technology, increasing healthcare expenditure, and growing awareness among patients and healthcare professionals. The market is also challenged by high treatment costs and the limited availability of effective therapies. Key players in the Short Bowel Syndrome market include Shire (Takeda), Nestle, and Zealand Pharma, among others, who are investing in research and development activities to bring new and improved treatment options to the market.
Major Players in the Short bowel Syndrome Industry:
Ardelyx, Inc.
Ardelyx, Inc. is a biopharmaceutical company founded in 2007 and headquartered in California, United States. The company is dedicated to the discovery, development, and commercialization of innovative treatments for cardiorenal and gastrointestinal diseases. In November 2021, Ardelyx, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its new drug, IBSRELA® (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Ardelyx, Inc. operates in the United States.
Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is a biopharmaceutical company founded in 2000 and headquartered in California, United States. The company is committed to discovering, developing, and commercializing innovative treatments and therapies for rare and orphan diseases. In September 2021, Emmaus Life Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its investigational drug, L-glutamine, for the treatment of short bowel syndrome. Emmaus Life Sciences, Inc. operates in the United States.
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. is a biotechnology company founded in 2017 and headquartered in California, United States. The company is focused on developing and commercializing innovative therapies for gastrointestinal and metabolic diseases. GLyPharma Therapeutic, Inc. is currently in preclinical development stages for its novel drug candidate, GLYX-13, for the treatment of short bowel syndrome. GLyPharma Therapeutic, Inc. operates in the United States.